BRCA2 and cervical carcinoma: Knockdown of BRCA1, BRCA2 or BRCA1/2 rendered TP53-deficient cervical cancer (HeLa) cells 4- to 7-fold more sensitive to cisplatin treatment than matched wild-type TP53 cells [25].